Lung Cancer Clinical Trial
Long-Term Follow-Up Study of Patients Receiving ATL001
This is an Open-Label, Multi-Centre Phase II study to evaluate the long-term safety and clinical activity of ATL001, previously administered intravenously to patients in Study ATX-NS-001 (NCT04032847) or Study ATX-ME-001 (NCT03997474).
Up to 90 patients with advanced non-small cell lung cancer ( NSCLC) or melanoma will be enrolled after either: completing 2 years of follow-up visits in study ATX-NS-001 or study ATX-ME-001; or voluntary withdrawal from these studies prior to the completion of the 2 year of follow-up period.
Each patient will be followed up for a minimum period of 5 years, or until death if sooner, in this Long-Term Follow Up Protocol.
For patients who are still alive after 5 years of follow-up, survival data will continue to be collected until the end of the study, which will occur when the last patient has completed 5 years of follow-up withdraws from study or has died.
Patients must have given written informed consent to participate in the study.
Patients must have received ATL001 in previous Clinical Trial ATX-NS-001 or ATX-ME-001.
Patients must be considered, in the opinion of the Investigator, capable of complying with the protocol requirements.
There are no exclusion criteria.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 7 Locations for this study
Tampa Florida, 33612, United States More Info
Birmingham , , United Kingdom More Info
Cambridge , , United Kingdom More Info
Leeds , LS97T, United Kingdom More Info
London , NW12P, United Kingdom More Info
London , SE19R, United Kingdom More Info
London , SW3 6, United Kingdom More Info
Manchester , M20 4, United Kingdom More Info
Newcastle Upon Tyne , NE7 7, United Kingdom More Info
Southampton , , United Kingdom More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.